SYGNIS AG Installs Scalable Production Capability for Lightning-Link Antibody Conjugation Technology

Jan 16, 2018

SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard), the Group which includes Expedeon Holdings, Innova Biosciences, and C.B.S. Scientific Company, today announced it has extended the manufacturing capability for its Lightning-Link® technology, currently marketed under the Innova Biosciences brand, to support scalability and bulk production of antibodies.   Lightning-Link is an innovative technology that enables direct labeling of antibodies or proteins in as little as 20 minutes, for use in R&D applications, drug discovery and the development of diagnostic kits. Lightning-Link kits are the world’s fastest, easiest to use and most efficient method of labeling antibodies or proteins, requiring only ...

Read More

Strategies for Developing a Cost-Efficient Pharmaceutical Manufacturing Process

Jan 4, 2018

In their paper, Valdas Jurkauskas and Xiaoyong Fu of STA Pharmaceuticals address the fact that manufacturing process throughput optimisation has become a necessity rather than an option. Only having high product yield, volumetrically efficient process and shortest possible production cycle time will enable the sponsor to withstand future increase in labour and utilities costs and reduce the probability of complex, expensive and risky post-approval changes. ...

Read More

Saneca Pharma strengthens team with new sales director

Dec 12, 2017

Slovakia-based contract development and manufacturing organization (CDMO) Saneca Pharma has strengthened its team with the appointment of a new CDMO sales director as it continues to implement its global growth strategy. With nearly 30 years’ experience in the industry, having held positions in a number of worldwide CDMO and contract research companies, Markus Saal joins the senior team at Saneca to head up its finished dosage form (FDF) sales and business development activity. He will work alongside Jan Bakta who will continue to lead its active pharmaceutical ingredient (API) business. Anthony Sheehan, CEO at Saneca Pharma said: “We are already ...

Read More

Phillips-Medisize Creates a Manufacturing Center of Excellence for Connected Health and Drug Delivery Devices

Dec 7, 2017

Phillips-Medisize, a Molex company, announces its initial investment to expand the capabilities of the 380,000 square foot Molex Little Rock facility to include a FDA registered manufacturing Center of Excellence for Connected Health and drug delivery devices. The construction of purpose-built clean room suites, as well as FDA registration and ISO 13485 certification are scheduled to be complete for its first customer’s production beginning in Q2 2018. This facility establishes a new manufacturing site in Little Rock, Arkansas for Phillips-Medisize’s medical business with capabilities for filling, drug handling, electronics and connected devices. This investment aims to combine the innovative solutions ...

Read More

PCI Announces Appointment to its Manufacturing Business Development Team

Dec 4, 2017

Leading pharmaceutical outsourcing services provider PCI Pharma Services has announced the appointment of Jennifer Goldberg to its Manufacturing Business Development team.   Jennifer joins PCI as Senior Account Executive, with responsibility for developing opportunities and building sales in PCI’s US West Coast territory to ensure continued growth and success in this key market.  Jennifer has an extensive background in drug development and manufacturing, with varying roles in business development at leading CMOs over a successful 20-year career.   Commenting on Jennifer’s appointment, Rob Jones, Business Development Director International at PCI, said: “We are delighted to welcome Jennifer to PCI.  She ...

Read More